| 常永莉,王惠琴,任加良,薛佩妮,陈方园,冉 兵.孟鲁司特联合信必可治疗支气管哮喘的疗效及对患者肺功能和血嗜酸细胞、C反应蛋白水平的影响[J].,2018,(23):4548-4551 |
| 孟鲁司特联合信必可治疗支气管哮喘的疗效及对患者肺功能和血嗜酸细胞、C反应蛋白水平的影响 |
| Clinical Efficacy of Montelukast Combined with Symbicort in the Treatment of Bronchial Asthma and Its Effect on the Lung Function and Blood Eosinophils, C-reactive Protein Levels |
| 投稿时间：2018-08-06 修订日期：2018-08-30 |
| DOI：10.13241/j.cnki.pmb.2018.23.035 |
| 中文关键词: 孟鲁司特 信必可 支气管哮喘 肺功能 炎症反应 |
| 英文关键词: Montelukast Symbicort Bronchial asthma Lung function Inflammation |
| 基金项目:陕西省自然科学基础研究计划项目(2014JM4186) |
|
| 摘要点击次数: 476 |
| 全文下载次数: 280 |
| 中文摘要: |
| 摘要 目的：探讨孟鲁司特联合信必可治疗支气管哮喘的疗效及对患者肺功能和血嗜酸细胞(EOS)、C反应蛋白(CRP)水平的影响。方法：选取我院2016年1月~2017年4月收治的136例支气管哮喘患者，按照随机数字表法均分为两组。对照组(68例)采取信必可治疗，观察组(68例)在此基础上加用孟鲁司特治疗。治疗12周后，评价两组的临床疗效，对比两组治疗前后哮喘症状评分、肺功能、外周血EOS计数及血清CRP水平变化的情况。结果：经12周治疗后，观察组总有效率为95.59%(65/68)，与对照组[79.41%(54/68)]相比显著上升(P<0.01)。与治疗前对比，两组治疗12周后日间与夜间哮喘评分、外周血EOS计数、血清CRP水平均显著下降(P<0.01)，且观察组以上指标均显著低于对照组(P<0.01)。与治疗前相比，两组治疗12周后肺功能指标FVC、FEV1、PEF值均有明显升高(P<0.01)；且观察组以上指标均显著高于对照组(P<0.01)。结论：孟鲁司特联合信必可治疗支气管哮喘可有效改善患者的肺功能，减轻气道炎症反应，促进哮喘症状缓解，疗效确切。 |
| 英文摘要: |
| ABSTRACT Objective: To explore clinical effect of montelukast combined with symbicort in the treatment of bronchial asthma and its effect on lung function and blood eosinophils, c-reactive protein. Methods: 136 cases with bronchial asthma who treated from January 2016 to April 2017 in our hospital, all were divided into two groups according to the random number table method.The control group (68 cases) was treated with symbicort, and the observation group(68 cases) was treated with montelukast based on the control group. After 12 weeks of treatment, the clinical efficacy, and the changes of asthma symptom score, lung function, peripheral blood EOS count and serum CRP level before and after treatment in both group were compared. Results: After 12 weeks of treatment, the total effective rate of the ob- servation group was 95.59%(65/68), which was significantly higher than the control group [79.41%(54/68)](P<0.01). Compared with be- fore treatment, the asthma score, peripheral blood EOS count, and serum CRP level in both groups were significantly decreased at 12 weeks after treatment(P<0.01), and the above indexes of the observation group were significantly lower than those of the control group (P<0.01). Compared with before treatment, the pulmonary function indexes FVC, FEV1 and PEF were significantly increased in both groups after 12 weeks of treatment(P<0.01). The above indexes in the observation group were significantly higher than those in the con- trol group(P<0.01). Conclusion: montelukast combined with cimb can effectively improve the lung function of patients with bronchial asthma, reduce airway inflammation and promote the relief of asthma symptoms. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
